The treatment continuum in the management of prostate cancer patients: What's new?

European Urology, Supplements

Volumn 5, Issue 7, 2006, Pages 539-542

  Saad, Fred ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Bisphosphonates; Bone loss; Bone pain; Chemotherapy; Hormone refractory prostate cancer; Skeletal complications; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; VACCINE; VITAMIN D; ZOLEDRONIC ACID;

ALOPECIA; BONE DISEASE; BONE METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CONFERENCE PAPER; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HORMONAL THERAPY; HUMAN; MORBIDITY; NAUSEA; NEUTROPENIA; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

EID: 33644837066     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.02.025     Document Type: Conference Paper

References (12)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. D.P. Petrylak, C.M. Tangen, and M.H.A. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
3. D.M. Preston, J.I. Torrens, and P. Harding Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss Prostate Cancer Prostatic Dis 5 2002 304 310
4. D. Mittan, S. Lee, and E. Miller Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs J Clin Endocrinol Metab 87 2002 3656 3661
5. R.E. Coleman Bisphosphonates: clinical experience Oncologist 9 2004 14 27
6. I.F. Tannock, D. Osoba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
7. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
8. M.R. Smith, J. Eastham, and D.M. Gleason Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012
9. S.M. Ali, F.J. Esteva, and G. Hortobagyi Safety and efficacy of bisphosphonates beyond 24 months in cancer patients J Clin Oncol 19 2001 3434 3437
10. L.S. Rosen, D. Gordon, and N.S. Tchekmedyian Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial Cancer 100 2004 2613 2621
11. P.R. Carroll, D. Neal, and H. Scher Management of disseminated prostate cancer L. Denis G. Bartsch S. Khoury Prostate Cancer: 3rd International Consultation on Prostate Cancer - Paris 2003 Health Publications Paris, France 251 284
12. A. Ullen, L. Lennartsson, and U. Harmenberg Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid Acta Oncol 44 2005 644 650